Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma

Annals of Surgery

Volumn 261, Issue 1, 2015, Pages 56-66

  Huang, Gang ^a   Lau, Wan Yee ^a,b   Wang, Zhen Guang ^a   Pan, Ze Ya ^a   Yuan, Sheng Xian ^a   Shen, Feng ^a   Zhou, Wei Ping ^a   Wu, Meng Chao ^a  

^a Eastern Hepatobiliary Surgery Hospital   (China)

^b and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

Author keywords

Antiviral therapy; Carcinoma; Hepatectomy; Hepatitis Bvirus; Hepatocellular; Prognosis

Indexed keywords

ADEFOVIR; ENTECAVIR; LAMIVUDINE; ADENINE; ANTIVIRUS AGENT; PHOSPHONIC ACID DERIVATIVE; VIRUS DNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL LABORATORY; CONTROLLED STUDY; DRUG SUBSTITUTION; FEMALE; HEPATITIS B; HUMAN; KIDNEY FUNCTION; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER RESECTION; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; SINGLE BLIND PROCEDURE; TUMOR GROWTH; TUMOR RECURRENCE; TUMOR VOLUME; ADOLESCENT; AGED; ANALOGS AND DERIVATIVES; BLOOD; CARCINOMA, HEPATOCELLULAR; GENETICS; HEPATITIS B, CHRONIC; LIVER FAILURE; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; NEOPLASM RECURRENCE, LOCAL; SURVIVAL; VIROLOGY; VIRUS ACTIVATION; YOUNG ADULT;

ADENINE; ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DNA, VIRAL; HEPATITIS B; HEPATITIS B, CHRONIC; HUMANS; LIVER FAILURE; LIVER NEOPLASMS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOPHOSPHONATES; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; VIRUS ACTIVATION; YOUNG ADULT;

EID: 84925012449     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000000858     Document Type: Article

References (40)

1. Gomaa AI, Khan SA, ToledanoMB, et al. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol. 2008; 14: 4300-4308.
2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003; 362: 1907-1917.
3. Bruix J, Llovet JM. Hepatitis B virus and hepatocellular carcinoma. J Hepatol. 2003; 39(suppl 1): S59-S63.
4. Poon RT, Fan ST, Lo CM, et al. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg. 2002; 235: 373-382.
5. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006; 295: 65-73.
6. Chan HL, Tse CH, Mo F, et al. High viral load and hepatitisBvirus subgenotype ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol. 2008; 26: 177-182.
7. Sun HC, Zhang W, Qin LX, et al. Positive serum hepatitis B e antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma. J Hepatol. 2007; 47: 684-690.
8. Hung IF, Poon RT, Lai CL, et al. Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection. Am J Gastroenterol. 2008; 103: 1663-1673.
9. Hoshida Y. Risk of recurrence in hepatitis B-related hepatocellular carcinoma: impact of viral load in late recurrence. J Hepatol. 2009; 51: 842-844.
10. An HJ, Jang JW, Bae SH, et al. Sustained low hepatitis B viral load predicts good outcome after curative resection in patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 2010; 25: 1876-1882.
11. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004; 351: 1521-1531.
12. Matsumoto A, Tanaka E, Rokuhara A, et al. Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: Amulticenter retrospective study of 2795 patients. Hepatol Res. 2005; 32: 173-184.
13. Hosaka T, Suzuki F, KobayashiM, et al. Long-termentecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology. 2013; 58: 98-107.
14. Singal AK, Salameh H, Kuo YF, et al. Meta-analysis: the impact of oral antiviral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B. Aliment Pharmacol Ther. 2013; 38: 98-106.
15. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001; 35: 421-430.
16. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999; 19(3): 329-338.
17. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005; 42: 1208-1236.
18. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007; 45: 507-539.
19. Kuzuya T, Katano Y, Kumada T, et al. Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma. J Gastroenterol Hepatol. 2007; 22: 1929-1935.
20. Jang JW, Choi JY, Bae SH, et al. Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma. J Hepatol. 2004; 41: 427-435.
21. Yeo W, Lam KC, Zee B, et al. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol. 2004; 15: 1661-1666.
22. Jang JW, Choi JY, Bae SH, et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology. 2006; 43: 233-240.
23. Mullen JT, Ribero D, Reddy SK, et al. Hepatic insufficiency and mortality in 1, 059 noncirrhotic patients undergoing major hepatectomy. J Am Coll Surg. 2007; 204: 854-862; discussion 862-864.
24. Pawlotsky JM, Dusheiko G, Hatzakis A, et al. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology. 2008; 134: 405-415.
25. Adachi E, Maeda T, Matsumata T, et al. Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma. Gastroenterology. 1995; 108: 768-775.
26. Poon RT, Fan ST, Ng IO, et al. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer. 2000; 89: 500-507.
27. Chuma M, Hige S, Kamiyama T, et al. The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma. J Gastroenterol. 2009; 44: 991-999.
28. Kubo S, Tanaka H, Takemura S, et al. Effects of lamivudine on outcome after liver resection for hepatocellular carcinoma in patients with active replication of hepatitis B virus. Hepatol Res. 2007; 37: 94-100.
29. Li N, Lai EC, Shi J, et al. A comparative study of antiviral therapy after resection of hepatocellular carcinoma in the immune-active phase of hepatitis B virus infection. Ann Surg Oncol. 2009; 17: 179-185.
30. Yin J, Li N, Han Y, et al. Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virusrelated hepatocellular carcinoma: a two-stage longitudinal clinical study. J Clin Oncol. 2013; 31: 3647-3655.
31. Lupberger J, Hildt E. Hepatitis B virus-induced oncogenesis. World J Gastroenterol. 2007; 13: 74-81.
32. Chen JD, Yang HI, Iloeje UH, et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology. 2010; 138: 1747-1754.
33. Kubo S, Hirohashi K, Tanaka H, et al. Effect of viral status on recurrence after liver resection for patients with hepatitis B virus-related hepatocellular carcinoma. Cancer. 2000; 88: 1016-1024.
34. Kubo S, Hirohashi K, Tanaka H, et al. Virologic and biochemical changes and prognosis after liver resection for hepatitis B virus-related hepatocellular carcinoma. Dig Surg. 2001; 18: 26-33.
35. Ko S, Nakajima Y, Kanehiro H, et al. Significant influence of accompanying chronic hepatitis status on recurrence of hepatocellular carcinoma after hepatectomy. Result of multivariate analysis. Ann Surg. 1996; 224: 591-595.
36. Shirabe K, Takenaka K, Taketomi A, et al. Postoperative hepatitis status as a significant risk factor for recurrence in cirrhotic patients with small hepatocellular carcinoma. Cancer. 1996; 77: 1050-1055.
37. Hoshida Y, Villanueva A, KobayashiM, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma.NEngl JMed. 2008; 359: 1995-2004.
38. Kubo S, Nishiguchi S, Hirohashi K, et al. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med. 2001; 134: 963-967.
39. Piao CY, Fujioka S, Iwasaki Y, et al. Lamivudine treatment in patients with HBV-related hepatocellular carcinoma-using an untreated, matched control cohort. Acta Med Okayama. 2005; 59: 217-224.
40. European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012; 57: 167-185.